AML1 mutations induced MDS and MDS/AML in a mouse BMT model Naoko Watanabe-Okochi

Naoko Watanabe-Okochi, Jiro Kitaura, Ryoichi Ono, Hironori Harada, Yuka Harada, Yukiko Komeno, Hideaki Nakajima, Tetsuya Nosaka, Toshiya Inaba, Toshio Kitamura

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Myelodysplastic syndrome (MDS) is a hematopoietic stem-cell disorder characterized by trilineage dysplasia and susceptibility to acute myelogenous leukemia (AML). Analysis of molecular basis of MDS has been hampered by the heterogeneity of the disease. Recently, mutations of the transcription factor AML1/RUNX1 have been identified in 15% to 40% of MDS-refractory anemia with excess of blasts (RAEB) and MDS/AML. We performed mouse bone marrow transplantation (BMT) using bone marrow cells transduced with the AML1 mutants. Most mice developed MDS and MDS/AML-like symptoms within 4 to 13 months after BMT. Interestingly, among integration sites identified, Evi1 seemed to collaborate with an AML1 mutant harboring a point mutation in the Runt homology domain (D171N) to induce MDS/AML with an identical phenotype characterized by marked hepatosplenomegaly, myeloid dysplasia, leukocytosis, and biphenotypic surface markers. Collaboration between AML1-D171N and Evi1 was confirmed by a BMT model where coexpression of AML1-D171N and Evi1 induced acute leukemia of the same phenotype with much shorter latencies. On the other hand, a C-terminal truncated AML1 mutant (S291fs×300) induced pancytopenia with erythroid dysplasia in transplanted mice, followed by progression to MDS-RAEB or MDS/AML. Thus, we have developed a useful mouse model of MDS/AML that should help in the understanding of the molecular basis of MDS and the progression of MDS to overt leukemia.

Original languageEnglish
Pages (from-to)4297-4308
Number of pages12
JournalBlood
Volume111
Issue number8
DOIs
Publication statusPublished - 2008 Apr 15
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Bone Marrow Transplantation
Acute Myeloid Leukemia
Bone
Mutation
Refractory materials
Stem cells
Refractory Anemia with Excess of Blasts
Transcription Factors
Cells
Leukemia
Phenotype
Pancytopenia
Leukocytosis
Hematopoietic Stem Cells
Point Mutation
Bone Marrow Cells

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Watanabe-Okochi, N., Kitaura, J., Ono, R., Harada, H., Harada, Y., Komeno, Y., ... Kitamura, T. (2008). AML1 mutations induced MDS and MDS/AML in a mouse BMT model Naoko Watanabe-Okochi. Blood, 111(8), 4297-4308. https://doi.org/10.1182/blood-2007-01-068346

AML1 mutations induced MDS and MDS/AML in a mouse BMT model Naoko Watanabe-Okochi. / Watanabe-Okochi, Naoko; Kitaura, Jiro; Ono, Ryoichi; Harada, Hironori; Harada, Yuka; Komeno, Yukiko; Nakajima, Hideaki; Nosaka, Tetsuya; Inaba, Toshiya; Kitamura, Toshio.

In: Blood, Vol. 111, No. 8, 15.04.2008, p. 4297-4308.

Research output: Contribution to journalArticle

Watanabe-Okochi, N, Kitaura, J, Ono, R, Harada, H, Harada, Y, Komeno, Y, Nakajima, H, Nosaka, T, Inaba, T & Kitamura, T 2008, 'AML1 mutations induced MDS and MDS/AML in a mouse BMT model Naoko Watanabe-Okochi', Blood, vol. 111, no. 8, pp. 4297-4308. https://doi.org/10.1182/blood-2007-01-068346
Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model Naoko Watanabe-Okochi. Blood. 2008 Apr 15;111(8):4297-4308. https://doi.org/10.1182/blood-2007-01-068346
Watanabe-Okochi, Naoko ; Kitaura, Jiro ; Ono, Ryoichi ; Harada, Hironori ; Harada, Yuka ; Komeno, Yukiko ; Nakajima, Hideaki ; Nosaka, Tetsuya ; Inaba, Toshiya ; Kitamura, Toshio. / AML1 mutations induced MDS and MDS/AML in a mouse BMT model Naoko Watanabe-Okochi. In: Blood. 2008 ; Vol. 111, No. 8. pp. 4297-4308.
@article{da66d5b4349c4ac09c42b93fb375c459,
title = "AML1 mutations induced MDS and MDS/AML in a mouse BMT model Naoko Watanabe-Okochi",
abstract = "Myelodysplastic syndrome (MDS) is a hematopoietic stem-cell disorder characterized by trilineage dysplasia and susceptibility to acute myelogenous leukemia (AML). Analysis of molecular basis of MDS has been hampered by the heterogeneity of the disease. Recently, mutations of the transcription factor AML1/RUNX1 have been identified in 15{\%} to 40{\%} of MDS-refractory anemia with excess of blasts (RAEB) and MDS/AML. We performed mouse bone marrow transplantation (BMT) using bone marrow cells transduced with the AML1 mutants. Most mice developed MDS and MDS/AML-like symptoms within 4 to 13 months after BMT. Interestingly, among integration sites identified, Evi1 seemed to collaborate with an AML1 mutant harboring a point mutation in the Runt homology domain (D171N) to induce MDS/AML with an identical phenotype characterized by marked hepatosplenomegaly, myeloid dysplasia, leukocytosis, and biphenotypic surface markers. Collaboration between AML1-D171N and Evi1 was confirmed by a BMT model where coexpression of AML1-D171N and Evi1 induced acute leukemia of the same phenotype with much shorter latencies. On the other hand, a C-terminal truncated AML1 mutant (S291fs×300) induced pancytopenia with erythroid dysplasia in transplanted mice, followed by progression to MDS-RAEB or MDS/AML. Thus, we have developed a useful mouse model of MDS/AML that should help in the understanding of the molecular basis of MDS and the progression of MDS to overt leukemia.",
author = "Naoko Watanabe-Okochi and Jiro Kitaura and Ryoichi Ono and Hironori Harada and Yuka Harada and Yukiko Komeno and Hideaki Nakajima and Tetsuya Nosaka and Toshiya Inaba and Toshio Kitamura",
year = "2008",
month = "4",
day = "15",
doi = "10.1182/blood-2007-01-068346",
language = "English",
volume = "111",
pages = "4297--4308",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - AML1 mutations induced MDS and MDS/AML in a mouse BMT model Naoko Watanabe-Okochi

AU - Watanabe-Okochi, Naoko

AU - Kitaura, Jiro

AU - Ono, Ryoichi

AU - Harada, Hironori

AU - Harada, Yuka

AU - Komeno, Yukiko

AU - Nakajima, Hideaki

AU - Nosaka, Tetsuya

AU - Inaba, Toshiya

AU - Kitamura, Toshio

PY - 2008/4/15

Y1 - 2008/4/15

N2 - Myelodysplastic syndrome (MDS) is a hematopoietic stem-cell disorder characterized by trilineage dysplasia and susceptibility to acute myelogenous leukemia (AML). Analysis of molecular basis of MDS has been hampered by the heterogeneity of the disease. Recently, mutations of the transcription factor AML1/RUNX1 have been identified in 15% to 40% of MDS-refractory anemia with excess of blasts (RAEB) and MDS/AML. We performed mouse bone marrow transplantation (BMT) using bone marrow cells transduced with the AML1 mutants. Most mice developed MDS and MDS/AML-like symptoms within 4 to 13 months after BMT. Interestingly, among integration sites identified, Evi1 seemed to collaborate with an AML1 mutant harboring a point mutation in the Runt homology domain (D171N) to induce MDS/AML with an identical phenotype characterized by marked hepatosplenomegaly, myeloid dysplasia, leukocytosis, and biphenotypic surface markers. Collaboration between AML1-D171N and Evi1 was confirmed by a BMT model where coexpression of AML1-D171N and Evi1 induced acute leukemia of the same phenotype with much shorter latencies. On the other hand, a C-terminal truncated AML1 mutant (S291fs×300) induced pancytopenia with erythroid dysplasia in transplanted mice, followed by progression to MDS-RAEB or MDS/AML. Thus, we have developed a useful mouse model of MDS/AML that should help in the understanding of the molecular basis of MDS and the progression of MDS to overt leukemia.

AB - Myelodysplastic syndrome (MDS) is a hematopoietic stem-cell disorder characterized by trilineage dysplasia and susceptibility to acute myelogenous leukemia (AML). Analysis of molecular basis of MDS has been hampered by the heterogeneity of the disease. Recently, mutations of the transcription factor AML1/RUNX1 have been identified in 15% to 40% of MDS-refractory anemia with excess of blasts (RAEB) and MDS/AML. We performed mouse bone marrow transplantation (BMT) using bone marrow cells transduced with the AML1 mutants. Most mice developed MDS and MDS/AML-like symptoms within 4 to 13 months after BMT. Interestingly, among integration sites identified, Evi1 seemed to collaborate with an AML1 mutant harboring a point mutation in the Runt homology domain (D171N) to induce MDS/AML with an identical phenotype characterized by marked hepatosplenomegaly, myeloid dysplasia, leukocytosis, and biphenotypic surface markers. Collaboration between AML1-D171N and Evi1 was confirmed by a BMT model where coexpression of AML1-D171N and Evi1 induced acute leukemia of the same phenotype with much shorter latencies. On the other hand, a C-terminal truncated AML1 mutant (S291fs×300) induced pancytopenia with erythroid dysplasia in transplanted mice, followed by progression to MDS-RAEB or MDS/AML. Thus, we have developed a useful mouse model of MDS/AML that should help in the understanding of the molecular basis of MDS and the progression of MDS to overt leukemia.

UR - http://www.scopus.com/inward/record.url?scp=43249103972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249103972&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-01-068346

DO - 10.1182/blood-2007-01-068346

M3 - Article

VL - 111

SP - 4297

EP - 4308

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -